ITI214

Research use only, not for human use.

ITI-214 is a potent, selective, orally active phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM.

ITI-214 is a potent, selective, orally active phosphodiesterase 1 (PDE1) inhibitor with Ki of 58 pM, displays >1,000-fold selectivity over PDE4A/4D and other PDE isoforms; improves the memory processes of acquisition, consolidation, and retrieval across a broad dose range (0.1-10 mg/kg, po) without disrupting the antipsychotic-like activity of a clinical antipsychotic medication, shows potential for schizophrenia and Alzheimer's disease, movement disorders, attention deficit and hyperactivity disorders, and other central nervous system (CNS) and non-CNS disorders.Parkinson Disease Phase 2 Clinical.

——

Animal Model:Male Sprague-Dawley rats Dosage:0.1-10 mg/kg Administration:p.o.Result:Significantly enhanced memory performance in the test with a minimum effective dose of 3 mg/kg.

ITI 214 | ITI-214

Angiogenesis

PDE

PDE

Neurological Disease

Parkinson Disease

1642303-38-5

605.5566

C29H29FN7O5P

>98% (HPLC)

DMSO: ≥ 30 mg/mL

CN1C(=O)C2=C(N(N=C2N3C1=NC4C3CCC4)CC5=CC=C(C=C5)C6=NC(=CC=C6)F)NC7=CC=CC=C7.OP(=O)(O)O

Cyclopent[4,5]imidazo[1,2-a]pyrazolo[4,3-e]pyrimidin-4(2H)-one, 2-[[4-(6-fluoro-2-pyridinyl)phenyl]methyl]-5,6a,7,8,9,9a-hexahydro-5-methyl-3-(phenylamino)-, (6aR,9aS)-, phosphate (1:1)

(-20℃)

With Ice Pack

≥ 2 years